Thomas Modine News Today

“Lifetime management” is the catchphrase in a range of sessions at PCR London Valves tackling TAVI’s unanswered big questions.

Odds of a study coming to fruition are low

May 21, 2021 Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR. On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches—annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement—aimed at...

Photo Credit: Hannes Alessandrini) As MitraClip procedures continue to expand as an option for nonsurgical patients with functional or degenerative mitral regurgitation (MR), a new question will increasingly arise: what’s the best approach for treating patients whose clip procedures fail? Now, a small, retrospective, single-center study is trying to shed some light. As Hannes Alessandrini, MD (Asklepios Klinik St. Georg, Hamburg, Germany), and colleagues write in EuroIntervention this month,...